{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:38:56Z","timestamp":1782337136579,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.semarthrit.2017.12.007","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T12:53:02Z","timestamp":1515156782000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis"],"prefix":"10.1016","volume":"48","author":[{"given":"Nitin K.","family":"Ahuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Mische","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M.","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna H.","family":"McMahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.12.007_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s40674-014-0005-0","article-title":"Management of gastrointestinal involvement in scleroderma","volume":"1","author":"Nagaraja","year":"2015","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/apt.13963","article-title":"Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis","volume":"45","author":"Kumar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib3","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gut.2005.086074","article-title":"A case\u2013control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma)","volume":"55","author":"Roberts","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib4","doi-asserted-by":"crossref","unstructured":"Mehndiratta M.M., Pandey S., Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2011; (2):CD006986. doi(2): CD006986.","DOI":"10.1002\/14651858.CD006986.pub2"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2006.06.018","article-title":"Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine","volume":"131","author":"Pasha","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MCG.0b013e318167b89d","article-title":"The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers","volume":"43","author":"Blonski","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10286-008-0476-x","article-title":"Pilot study of pyridostigmine in constipated patients with autonomic neuropathy","volume":"18","author":"Bharucha","year":"2008","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1463-1318.2009.01838.x","article-title":"The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine","volume":"12","author":"O'Dea","year":"2010","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/gutjnl-2012-302483","article-title":"A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation","volume":"62","author":"Bharucha","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2008.04.009","article-title":"Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility","volume":"6","author":"Dhamija","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/0003-4819-94-6-749","article-title":"Abnormal colonic motility in progressive systemic sclerosis","volume":"94","author":"Battle","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib12","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/nmo.12669","article-title":"Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders","volume":"27","author":"Parthasarathy","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib13","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: An american college of rheumatology\/european league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib14","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib16","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","article-title":"Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenia syndrome","volume":"20","author":"Oh","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/mus.25625","article-title":"Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis","author":"Machado-Alba","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2017.12.007_bib19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) Instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Athritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217305498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217305498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T22:23:01Z","timestamp":1570573381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217305498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0049017217305498"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.12.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}